{
  "docId": "019de075-d132-769f-97bd-4a840dd24899",
  "docSlug": "9e6f6ffb1a7ecb278276dcbd68bd1d77",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 56 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 56,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 11,
  "notes": "The slide uses a bar chart to show benchmark data alongside a specific exposure-response analysis for vedolizumab.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-d132-769f-97bd-4a840dd24899/24",
  "deckHref": "/decks/019de075-d132-769f-97bd-4a840dd24899",
  "deckJsonHref": "/decks/019de075-d132-769f-97bd-4a840dd24899.json",
  "deckAnchorHref": "/decks/019de075-d132-769f-97bd-4a840dd24899#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.55,
        "x": 0.02,
        "y": 0.225
      },
      "kind": "chart",
      "text": "UC induction clinical remission rates",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bfe97c1-c509-41ac-a76e-e07888ba976b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.38,
        "x": 0.6,
        "y": 0.25
      },
      "kind": "list",
      "text": "Slow onset of vedolizumab efficacy may be explained by insufficient dosing. Clear exposure-efficacy relationship observed at Week 6: Highest quartile achieved a remarkable 37.1% remission rate. Lowest exposure quartile did not separate from placebo.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4dae49d7-064a-46a3-9953-24800281e34f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.38,
        "x": 0.6,
        "y": 0.6
      },
      "kind": "paragraph",
      "text": "FDA noted \"significant exposure-response relationship\" and recommended exploring higher doses to improve remission rates.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "510fe1a7-fa2e-46ca-91dc-c863f2549b54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.95,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1. Rosario, M., et. al. (2017). 2. Vedolizumab FDA Clinical Pharmacology Review. Figure sources: Multi-MOA benchmark data from adalimumab label (TNFa), ustekinumab label (IL-12/23), mirikizumab LUCENT-1 study (IL-23), PRA023 P2b (TL1A), and vedolizumab VARSITY study (a4b7). Vedolizumab exposure-response data from Rosario, M., et. al. (2017).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e011e230-abd3-4bb3-9fa8-73ffa20cfa55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Vedolizumab appears underdosed in induction; opportunity for SPY001 to achieve superior time to onset",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eab761a5-2646-471e-9755-d6ee812087fb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "39ec9092-b053-4a31-ab77-36ade4a23238",
      "evidence": "Comparing benchmark MOA data against specific drug exposure quartiles to identify a market opportunity.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 44,
      "from": 10,
      "beatId": "4a77d9e6-a2c5-4533-8a36-dd4f9e373789",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Spyre's pipeline and solution for IBD treatment.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}